Literature DB >> 18292565

Antiviral activity of the long chain pentraxin PTX3 against influenza viruses.

Patrick C Reading1, Silvia Bozza, Brad Gilbertson, Michelle Tate, Silvia Moretti, Emma R Job, Erika C Crouch, Andrew G Brooks, Lorena E Brown, Barbara Bottazzi, Luigina Romani, Alberto Mantovani.   

Abstract

Proteins of the innate immune system can act as natural inhibitors of influenza virus, limiting growth and spread of the virus in the early stages of infection before the induction of adaptive immune responses. In this study, we identify the long pentraxin PTX3 as a potent innate inhibitor of influenza viruses both in vitro and in vivo. Human and murine PTX3 bound to influenza virus and mediated a range of antiviral activities, including inhibition of hemagglutination, neutralization of virus infectivity and inhibition of viral neuraminidase. Antiviral activity was associated with binding of the viral hemagglutinin glycoprotein to sialylated ligands present on PTX3. Using a mouse model we found PTX3 to be rapidly induced following influenza infection and that PTX3-/- mice were more susceptible than wild-type mice to infection by PTX3-sensitive virus strains. Therapeutic treatment of mice with human PTX3 promoted survival and reduced viral load in the lungs following infection with PTX3-sensitive, but not PTX3-resistant, influenza viruses. Together, these studies describe a novel antiviral role for PTX3 in early host defense against influenza infections both in vitro and in vivo and describe the therapeutic potential of PTX3 in ameliorating disease during influenza infection.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18292565     DOI: 10.4049/jimmunol.180.5.3391

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  92 in total

1.  Risk factors for chronic kidney diseases may include periodontal diseases, as estimated by the correlations of plasma pentraxin-3 levels: a case-control study.

Authors:  A R Pradeep; Rahul Kathariya; P Arjun Raju; R Sushma Rani; Anuj Sharma; N M Raghavendra
Journal:  Int Urol Nephrol       Date:  2011-06-03       Impact factor: 2.370

2.  Neuraminidase Activity and Resistance of 2009 Pandemic H1N1 Influenza Virus to Antiviral Activity in Bronchoalveolar Fluid.

Authors:  Kanyarat Ruangrung; Ornpreya Suptawiwat; Kittipong Maneechotesuwan; Chompunuch Boonarkart; Warunya Chakritbudsabong; Jirawatna Assawabhumi; Parvapan Bhattarakosol; Mongkol Uiprasertkul; Pilaipan Puthavathana; Witthawat Wiriyarat; Anan Jongkaewwattana; Prasert Auewarakul
Journal:  J Virol       Date:  2016-04-14       Impact factor: 5.103

3.  Salivary Blockade Protects the Lower Respiratory Tract of Mice from Lethal Influenza Virus Infection.

Authors:  Karen Ivinson; Georgia Deliyannis; Leanne McNabb; Lara Grollo; Brad Gilbertson; David Jackson; Lorena E Brown
Journal:  J Virol       Date:  2017-06-26       Impact factor: 5.103

Review 4.  Newer influenza antivirals, biotherapeutics and combinations.

Authors:  Frederick G Hayden
Journal:  Influenza Other Respir Viruses       Date:  2013-01       Impact factor: 4.380

5.  Bacterial Outer Membrane Vesicles Provide Broad-Spectrum Protection against Influenza Virus Infection via Recruitment and Activation of Macrophages.

Authors:  Eun-Hye Bae; Sang Hwan Seo; Chang-Ung Kim; Min Seong Jang; Min-Suk Song; Tae-Young Lee; Yu-Jin Jeong; Moo-Seung Lee; Jong-Hwan Park; Pureum Lee; Young Sang Kim; Sang-Hyun Kim; Doo-Jin Kim
Journal:  J Innate Immun       Date:  2019-03-07       Impact factor: 7.349

6.  Persisting high levels of plasma pentraxin 3 over the first days after severe sepsis and septic shock onset are associated with mortality.

Authors:  Tommaso Mauri; Giacomo Bellani; Nicolo' Patroniti; Andrea Coppadoro; Giuseppe Peri; Ivan Cuccovillo; Massimo Cugno; Gaetano Iapichino; Luciano Gattinoni; Antonio Pesenti; Alberto Mantovani
Journal:  Intensive Care Med       Date:  2010-01-30       Impact factor: 17.440

7.  Galectin-1 binds to influenza virus and ameliorates influenza virus pathogenesis.

Authors:  Mei-Lin Yang; Yu-Hung Chen; Shainn-Wei Wang; Yen-Jang Huang; Chia-Hsing Leu; Nai-Chi Yeh; Chun-Yen Chu; Chia-Cheng Lin; Gia-Shing Shieh; Yuh-Ling Chen; Jen-Ren Wang; Ching-Ho Wang; Chao-Liang Wu; Ai-Li Shiau
Journal:  J Virol       Date:  2011-07-27       Impact factor: 5.103

8.  Cellular transcripts regulated during infections with Highly Pathogenic H5N1 Avian Influenza virus in 3 host systems.

Authors:  Vinod Rmt Balasubramaniam; Sharifah S Hassan; Abdul R Omar; Maizan Mohamed; Suriani M Noor; Ramlan Mohamed; Iekhsan Othman
Journal:  Virol J       Date:  2011-04-29       Impact factor: 4.099

9.  Innate immunity to influenza virus: implications for future therapy.

Authors:  Mitchell R White; Mona Doss; Patrick Boland; Tesfaldet Tecle; Kevan L Hartshorn
Journal:  Expert Rev Clin Immunol       Date:  2008-07-01       Impact factor: 4.473

Review 10.  Animal models for the study of influenza pathogenesis and therapy.

Authors:  Dale L Barnard
Journal:  Antiviral Res       Date:  2009-01-25       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.